Altimmune, Inc. (ALT) SEC Filing 8-K Material Event for the period ending Thursday, September 26, 2019

Altimmune, Inc.

CIK: 1326190 Ticker: ALT

View differences made from one to another to evaluate Altimmune, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Altimmune, Inc..


Assess how Altimmune, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Altimmune, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: ALT
CIK: 1326190
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-259847
Submitted to the SEC: Tue Oct 01 2019 4:06:06 PM EST
Accepted by the SEC: Tue Oct 01 2019
Period: Thursday, September 26, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit
  3. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: